Consistent with this, the 2017 update of the European LeukemiaNet (ELN) recommendations for the diagnosis and management of AML in adults emphasized the prognostic impact of FLT3-ITD and integrated the FLT3-ITD allelic ratio (AR) into the ELN risk stratification [20]. This evidence concerns the gene FLT3 and acute myeloid leukemia.